Cargando…
Engaging Patients with Depression in Treatment Continuity
When conceptualising engagement with treatment, it may be useful to contrast ‘disease’, which refers to underlying psychobiological dysfunction, with ‘illness’, which describes the experience of the person with that disease. Knowledge of disease, as well as understanding of illness, including patien...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016040/ https://www.ncbi.nlm.nih.gov/pubmed/35247182 http://dx.doi.org/10.1007/s12325-021-02029-6 |
_version_ | 1784688443366834176 |
---|---|
author | Stein, Dan J. |
author_facet | Stein, Dan J. |
author_sort | Stein, Dan J. |
collection | PubMed |
description | When conceptualising engagement with treatment, it may be useful to contrast ‘disease’, which refers to underlying psychobiological dysfunction, with ‘illness’, which describes the experience of the person with that disease. Knowledge of disease, as well as understanding of illness, including patients’ explanatory models of symptoms, may be useful in facilitating shared decision-making. Ideally, physicians are able to integrate evidence-based medicine with values-based medicine by combining the best research evidence with patients’ unique needs and preferences. This, in turn, requires taking a systematic approach to the assessment of a range of domains (i.e. symptom profile, clinical subtype, severity and comorbidity) in individuals with depression, and individualising treatment accordingly. While data are now available from a range of randomised clinical trials addressing treatments for depressive symptoms, it is also notable that a decrease in symptom severity does not necessarily correlate with an increase in functioning, which highlights the need to monitor patients for the effect of treatment on a range of outcomes including comorbid anxiety, emotional responsiveness, and sleep quality. Importantly, recent epidemiological data emphasise the importance of persistence with treatment; most patients with major depression who persist with treatment eventually feel helped. |
format | Online Article Text |
id | pubmed-9016040 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-90160402022-05-02 Engaging Patients with Depression in Treatment Continuity Stein, Dan J. Adv Ther Commentary When conceptualising engagement with treatment, it may be useful to contrast ‘disease’, which refers to underlying psychobiological dysfunction, with ‘illness’, which describes the experience of the person with that disease. Knowledge of disease, as well as understanding of illness, including patients’ explanatory models of symptoms, may be useful in facilitating shared decision-making. Ideally, physicians are able to integrate evidence-based medicine with values-based medicine by combining the best research evidence with patients’ unique needs and preferences. This, in turn, requires taking a systematic approach to the assessment of a range of domains (i.e. symptom profile, clinical subtype, severity and comorbidity) in individuals with depression, and individualising treatment accordingly. While data are now available from a range of randomised clinical trials addressing treatments for depressive symptoms, it is also notable that a decrease in symptom severity does not necessarily correlate with an increase in functioning, which highlights the need to monitor patients for the effect of treatment on a range of outcomes including comorbid anxiety, emotional responsiveness, and sleep quality. Importantly, recent epidemiological data emphasise the importance of persistence with treatment; most patients with major depression who persist with treatment eventually feel helped. Springer Healthcare 2022-03-05 2022 /pmc/articles/PMC9016040/ /pubmed/35247182 http://dx.doi.org/10.1007/s12325-021-02029-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Commentary Stein, Dan J. Engaging Patients with Depression in Treatment Continuity |
title | Engaging Patients with Depression in Treatment Continuity |
title_full | Engaging Patients with Depression in Treatment Continuity |
title_fullStr | Engaging Patients with Depression in Treatment Continuity |
title_full_unstemmed | Engaging Patients with Depression in Treatment Continuity |
title_short | Engaging Patients with Depression in Treatment Continuity |
title_sort | engaging patients with depression in treatment continuity |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016040/ https://www.ncbi.nlm.nih.gov/pubmed/35247182 http://dx.doi.org/10.1007/s12325-021-02029-6 |
work_keys_str_mv | AT steindanj engagingpatientswithdepressionintreatmentcontinuity |